DTaP-IPV vaccine is a combination vaccine whose full generic name is diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine (IPV).[1][2]

It is also known as DTaP/IPV, dTaP/IPV, DTPa-IPV, or DPT-IPV.[1] It protects against the infectious diseases diphtheria, tetanus, pertussis, and poliomyelitis.[1]

Branded formulations marketed in the USA are Kinrix from GlaxoSmithKline[3] and Quadracel from Sanofi Pasteur.[4]

Repevax is available in the UK.[5][6]

Within Japan, the formulation is called 四種混合(shishukongou - "mixture of 4"). Astellas markets it under the クアトロバック ('Quattro-back') formulation, while another is available from Mitsubishi Tanabe Pharma named テトラビック ('Tetrabic').[7][8] A previous product by Takeda Pharmaceutical Company has been withdrawn by the company.[9]

References

  1. ^ a b c "Diphtheria, Tetanus, Pertussis (Acellular, Component) And Poliomyelitis (Inactivated) Vaccine (Adsorbed)". Drugs.com. Retrieved 15 July 2018.
  2. ^ Syed YY (October 2019). "DTaP-IPV-HepB-Hib Vaccine (Hexyon®): An Updated Review of its Use in Primary and Booster Vaccination". Paediatric Drugs. 21 (5): 397–408. doi:10.1007/s40272-019-00353-7. PMC 6794236. PMID 31444785.
  3. ^ "Kinrix". US Food and Drug Administration. Retrieved 15 July 2018.
  4. ^ "Quadracel". US Food and Drug Administration. Retrieved 15 July 2018.
  5. ^ "Repevax, suspension for injection, in pre-filled syringe - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 31 December 2020.
  6. ^ "14. Vaccines". British National Formulary (BNF) (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1381. ISBN 978-0-85711-369-6.
  7. ^ "医療用医薬品 : テトラビック (テトラビック皮下注シリンジ)". www.kegg.jp. Retrieved 2021-02-27.
  8. ^ "医療用医薬品 : クアトロバック (クアトロバック皮下注シリンジ)". www.kegg.jp. Retrieved 2021-02-27.
  9. ^ "【武田薬品】４種混合ワクチンの開発中止-ノロウイルスなどに資源投入｜薬事日報ウェブサイト". 9 February 2015. Retrieved 2021-02-27.